CADL
Candel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.78
−1.46%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.0x
Market Cap
$977.91M
MomentumView details →
1D Return
−1.46%
YTD Return
+130.09%
RSI (14)
59.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.0x
Market Cap
$977.91M
RSI (14)
59.2
MomentumView details →
1D Return
−1.46%
YTD Return
+130.09%
SummaryUpdated Jun 1, 2026
Candel Therapeutics, Inc. (NASDAQ:CADL) is a clinical-stage biopharmaceutical company founded in 2003 and headquartered in Needham, Massachusetts. Originally incorporated as Advantagene, Inc., the company rebranded to Candel Therapeutics in November 2020 before going public in July 2021. The company focuses on developing innovative immunotherapies designed to treat various forms of cancer by harnessing the body's immune system to fight tumors.
Similar companies
Latest newsMore news →
Candel Therapeutics announced its financial results for the second quarter ended June 30, 2026.23d agoCandel Therapeutics initiated a global pivotal Phase 3 AURORA trial evaluating aglatimagene besadenovec (CAN-2409) in advanced non-small cell lung cancer patients with inadequate response to immune checkpoint inhibitors.67d agoCandel Therapeutics granted stock options to three new employees on May 31, 2026.95d ago